# A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

Study · id `cardio:ct-nct07311551` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07311551](<https://clinicaltrials.gov/study/NCT07311551>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07311551

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 112 participants.

## Technical summary

Registry record NCT07311551. Randomized; no masking; primary purpose treatment. Start 2025-12-24 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 112 participants (planned count; ClinicalTrials.gov record NCT07311551, source copy `cardio:ctgov-nct07311551-2025-12-31`, retrieved 2026-10-26)
- Planned start: 2025-12-24 (anticipated) (ClinicalTrials.gov record NCT07311551, source copy `cardio:ctgov-nct07311551-2025-12-31`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07311551, source copy `cardio:ctgov-nct07311551-2025-12-31`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07311551, source copy `cardio:ctgov-nct07311551-2025-12-31`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07311551-2025-12-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
- Condition: Type 2 Diabetes
- Intervention (Drug): Dapagliflozin (10Mg Tab) along with standard medical therapy
- Intervention (Drug): Empagliflozin (25 Mg Tab) along with standard medical therapy
- Lead sponsor: Bhavya Bhavya, MD
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 1a3782daffe47698a2f6ca1dc63f196c2a2fdfe5bb786edfefffc0fffcf5fcb4
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
